No Increased VTE Risk with Continued HT During Gender-Affirming Surgery
Transgender and gender nonbinary patients who remain on estrogen hormone therapy during gender-affirming surgery do not have an increased risk for venous thromboembolism, according to findings published in The Journal of Clinical Endocrinology & Metabolism.